Retraction Note: Acute myeloid leukemia-derived exosomes deliver miR-24-3p to hinder the T-cell immune response through DENN/MADD targeting in the NF-κB signaling pathways.

Khalid Otmani, Redouane Rouas, Laurence Lagneaux, Mohammad Krayem, Hugues Duvillier, Mimoune Berehab, Philippe Lewalle

Abstract readRetraction Notice

In one paragraph

Article in Cell communication and signaling : CCS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

Retraction of
Acute myeloid leukemia-derived exosomes deliver miR-24-3p to hinder the T-cell immune response through DENN/MADD targeting in the NF-κB signaling pathways.2023

5 · Who and what money

Authors and funding

7 authors.

Khalid OtmaniExperimental Hematology Laboratory, Hematology Department, Hôpital Universitaire de Bruxelles, (H.U.B.) Institut Jules Bordet, Université Libre de Bruxelles, 90 Meylemeersch Street, Brussels, 1070, Belgium. otmani_khalid001@hotmail.com.

Redouane RouasExperimental Hematology Laboratory, Hematology Department, Hôpital Universitaire de Bruxelles, (H.U.B.) Institut Jules Bordet, Université Libre de Bruxelles, 90 Meylemeersch Street, Brussels, 1070, Belgium.

Laurence LagneauxLaboratoire de Thérapie Cellulaire Clinique (LTCC), Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.

Mohammad KrayemLaboratory of Clinical and Experimental Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.

Hugues DuvillierFlow Cytometry Facility, Hôpital Universitaire de Bruxelles (H.U.B.) Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.

Mimoune BerehabExperimental Hematology Laboratory, Hematology Department, Hôpital Universitaire de Bruxelles, (H.U.B.) Institut Jules Bordet, Université Libre de Bruxelles, 90 Meylemeersch Street, Brussels, 1070, Belgium.

Philippe LewalleExperimental Hematology Laboratory, Hematology Department, Hôpital Universitaire de Bruxelles, (H.U.B.) Institut Jules Bordet, Université Libre de Bruxelles, 90 Meylemeersch Street, Brussels, 1070, Belgium. Philippe.lewalle@hubruxelles.be.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID41350690

DOI10.1186/s12964-025-02574-5

PMCPMC12679768

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.